AVAST-M Trial – Final Results Announced

The final results of this major clinical trial were announced in June 2017 at the American Society of Clinical Oncology (ASCO) conference in Chicago.

Dr Pippa Corrie, AVAST-M Trial Chief Investigator, comments:

‘I would like to renew our thanks to all those who took part in the AVAST-M trial. Although the results confirm that Avastin should not become a standard treatment after melanoma surgery, we have learned a great deal through this clinical trial and these conclusions will help shape the future of melanoma treatments.

‘The contribution of those who participated in AVAST-M was thoroughly worthwhile and will benefit others suffering from this disease in future’.

Please see The AVAST-M Patient Newsletter for further details







printer-friendly version